Exabis Library
Welcome to the e-CCO Library!
P477: Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P477: The efficacy of adalimumab for the treatment of Korean patients with ulcerative colitis and predictors of response: Preliminary results
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P478 Thiopurines’ metabolites levels and drug toxicity: a systematic review and meta-analysis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P478: Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy: an observational multicentre study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P478: How often high-dose budesonide is necessary for maintenance treatment of collagenous colitis? Efficacy of azathioprine to maintain budesonide-free clinical remission
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P478: Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P478: Platelet-related indicators for predicting vedolizumab response in patients with Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P478: The current place of probiotics in treatment of pouchitis: systematic review
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P478: The role of proactive measurement of adalimumab trough levels and antibodies to adalimumab in Greek patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P478: Treatment with ferric maltol associated with improvements in quality of life for IBD patients with iron deficiency anaemia
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P479 The effect of adalimumab on linear growth in children with Crohn’s disease: a post hoc analysis of the PAILOT randomised control trial
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P479: Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P479: Biological therapies and bio-microbial dynamics in inflammatory bowel diseases
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P479: Hepcidin and the risk of malnutrition in inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P479: Quality of care and outcomes in a tertiary hospital inflammatory bowel disease (IBD) centre: Monitoring and treatment algorithms during follow-up
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P479: Reliability and responsiveness of histologic disease activity indices in Crohn's Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P479: Shifting the shunters in a paediatric inflammatory bowel disease population: thiopurine dose splitting versus allopurinol and thiopurine co-therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P479: Trends in medication use and treatment patterns in Chinese patients with Inflammatory Bowel Diseases: A multicenter cohort study from 1999 to 2020
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P480 Efficiency and safety of endoscopic balloon dilatation of ileocolonic anastomotic strictures in patients with Crohn’s disease: A multicentric retrospective study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P480: Assessing primary response to biologic therapy in Inflammatory Bowel Disease - ‘the when and the how?’
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM